Data released from a successful phase 3 trial validate an approach that Rockefeller’s Nathaniel Heintz has pioneered for decades—and could pave the way for a new generation of neurological drugs.
Nathaniel Heintz has spent decades building tools to peer inside individual brain cell types—now he's using those tools to spot some of the earliest changes that occur in neurodegenerative diseases.
Hironori Funabiki studies how the chromosomes carrying our genomic DNA are copied and maintained. His basic research is shedding light on cancer, rare immune diseases, and even how our bodies recognize viruses.
Cysteine is essential for life, but toxic in excess. A new study reveals why: free cysteine can unleash stored iron, overwhelming mitochondria and triggering a form of cell death.
A large clinical trial shows that long-acting antibodies may work with the immune system to control HIV and help reduce the reservoir that would make lifelong treatment necessary.
Brief bursts of intense exercise trigger a molecular response linked to a lower risk of cardiovascular and metabolic disease and that are associated with slower biological aging.
A new protein-tracing platform reveals how fat and liver cells communicate during fasting, inflammation, and obesity, and links many of those signals to human disease.
